Shares of ImmuPharma PLC (LON: IMM) fell 10% after the company revealed that its US licensing partner Avion was yet to receive a response from the US Food & Drug Administration (FDA) regarding its application for the assessment of Lupuzor’s Phase III trial.
The company clarified that the application was still pending before the FDA in a review queue due to the FDA’s current heavy workload.
Lupuzor is a drug targeted at treating lupus, a systemic autoimmune disease, which usually leads to the bodies immune system attacking its own organs and tissues.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
ImmuPharma issued the update given that the 45-day review period usually allocated by the FDA for such applications had passed with no feedback from the regulator.
The pharmaceutical company recently raised £6.5 million through an oversubscribed share placement that triggered a significant drop in its share price since the new shares were priced at a significant discount.
The firm promised to issue an update once it receives a response from the FDA.
Immupharma share price
Immupharma shares today fell 10% to trade at 12.15p having ended Thursday’s session trading at 13.50p.
People who read this also read:
